Detalhe da pesquisa
1.
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Breast Cancer Res
; 19(1): 98, 2017 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28830573
2.
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.
NPJ Breast Cancer
; 3: 4, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28649644
3.
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.
Oncotarget
; 7(47): 77358-77364, 2016 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27764800
4.
Cardiac dysfunction in clinical trials of trastuzumab.
J Clin Oncol
; 20(19): 4119; author reply 4120, 2002 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12351610
5.
Stage-related changes in functional capacity in Hodgkin's disease: assessment by cardiopulmonary exercise testing before initiation of treatment.
Ann Hematol
; 85(12): 857-61, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16969675
6.
Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens.
Gynecol Oncol
; 88(3): 351-7, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12648586